Adam M Veness has sold stock and made no open-market buys since Aug 2019
SVP, General Counsel and Sec. at Dianthus Therapeutics, Inc., and 1 other company
SEC CIK 0001778623 · Filings on SEC.gov ↗
Companies
Every filing
10 filings since Aug 2019, newest first
Dianthus Therapeutics, Inc. /DE/
SVP, General Counsel and Sec.
Dianthus Therapeutics, Inc. /DE/
SVP, General Counsel and Sec.
Acceleron Pharma Inc
SVP, GC, Sec.
Acceleron Pharma Inc
SVP, GC, Sec.
Acceleron Pharma Inc
SVP, GC, Sec.
Acceleron Pharma Inc
SVP, GC, Sec.
Acceleron Pharma Inc
SVP, GC, Sec.
Acceleron Pharma Inc
VP, GC, Sec.
Acceleron Pharma Inc
VP, GC, Sec.
Acceleron Pharma Inc
VP, GC, Sec.
About Adam M Veness
Adam M. Veness, Esq. is a life sciences legal executive who served as Senior Vice President, General Counsel and Secretary at Acceleron Pharma Inc. (XLRN), where he oversaw all aspects of legal and compliance, including SEC reporting, capital markets, corporate governance, contracts, intellectual property, employment matters, and data privacy.( In that role, he also acted as a corporate officer and signatory on SEC filings for Acceleron Pharma, reflecting his responsibilities as a corporate insider.( Following Acceleron’s acquisition by Merck, Veness continued his career in biopharmaceuticals, later becoming General Counsel and Secretary at Cyteir Therapeutics and subsequently SVP, General Counsel at Dianthus Therapeutics, Inc.(
Veness is an experienced legal professional with a demonstrated history in the biopharmaceutical industry, having held senior leadership positions that span public company compliance, strategic transactional support, and corporate governance for emerging and established life sciences organizations.( He earned a B.A., cum laude, in Political Science and Philosophy from Tulane University and a J.D., cum laude, from Boston University School of Law, providing the academic foundation for his work at the intersection of law and biotechnology.( As a senior legal leader and corporate insider, his career highlights include guiding Acceleron Pharma through complex regulatory and capital markets matters and contributing to executive management teams at multiple innovative therapeutics companies.(
Written by Perplexity from public sources.
Filings come from SEC EDGAR. Not investment advice.